Halozyme (HALO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$110.19-0.51%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · HALO
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks HALO against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue driving total revenue and royalty revenue growth through new collaborations, product launches, and expanded indications.
Stated as a priority in 4 of last 4 quarters. Total revenue grew from $325.7 million in 2025-Q2 to $481 million in 2026-Q2 (+48%), and royalty revenue grew from $205.6 million to $308 million (+50%) in the same period. Full year 2025 revenue was $1.397 billion, up 38% from 2024, with royalty revenue up 52%. Management has consistently emphasized revenue growth and is delivering on this trajectory.
“Total revenue increased 48% year-over-year to $481 million, royalty revenue increased 50% to $308 million.”
“Total revenue increased 42% YOY to $377 million, royalty revenue increased 43% YOY to $241 million.”
“Full year 2025 total revenue increased 38% YOY to $1.397 billion, royalty revenue increased 52% YOY to $868 million.”
“Total revenue was $325.7 million, royalty revenue $205.6 million, reflecting growth over prior periods.”
Improve operating income through revenue growth and managing expenses, including integration of acquisitions.
Management stated this priority in 4 of last 4 quarters. Operating income rose from $202.4 million in 2025-Q2 to $287.7 million in 2026-Q2, and from $141.5 million in 2025-Q1 to $184.5 million in 2026-Q1, showing improvement alongside revenue growth. The trajectory is delivering on enhanced operating income.
“Operating income was $287.7 million, compared to $202.4 million in 2025-Q2.”
Maintain strong cash generation from operating activities to support investments and capital return programs.
Stated in 4 of last 4 quarters. Cash from operations increased from $99.7 million in 2025-Q2 to $180.1 million in 2026-Q1. Cash, cash equivalents and marketable securities were $231.9 million at 2026-Q2 end. Management's focus on cash generation is reflected in improving cash flow and liquidity, delivering on this priority.
“Cash, cash equivalents, restricted cash and marketable securities were $231.9 million on June 30, 2026.”
Grow and diversify drug delivery technology offerings through acquisitions of Elektrofi and Surf Bio technologies.
Stated in 3 of last 3 quarters. The acquisitions of Elektrofi and Surf Bio completed in late 2025 expanded Halozyme's drug delivery technology portfolio. Incremental operating expenses of about $55 million are expected in 2026 due to these acquisitions. Management is delivering on this strategic expansion priority.
Return capital through a $1 billion share repurchase program with at least $400 million planned for 2026.
Stated in 2 of last 2 quarters. Management announced a $1 billion share repurchase program in 2026-Q1 with a plan to repurchase at least $400 million in 2026. By 2026-Q2, $333 million of shares were repurchased. The company is delivering on its capital return commitment.
“Repurchased 4.8 million shares for $332.8 million in 2Q 2026 under share repurchase programs.”
Over the trailing year it converted 1.32x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to real (inflation-adjusted) rates, long-term interest rates, the US dollar, Fed net liquidity (low R² over the window).
16 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“Operating income was $184.5 million, compared to $141.5 million in 2025-Q1.”
“Operating income was $175.5 million, compared to $163.2 million in 2024-Q3.”
“Operating income was $202.4 million, compared to $117.2 million in 2024-Q2.”
“Cash, cash equivalents, restricted cash and marketable securities were $320.9 million on March 31, 2026.”
“Cash, cash equivalents, restricted cash and marketable securities were $145.4 million on December 31, 2025.”
“Cash from operating activities was $99.7 million in 2025-Q2.”
“Increase in R&D expense due to acquisition of Elektrofi and Surf Bio in Q4 2025.”
“Completed acquisitions of Elektrofi and Surf Bio, expanding drug delivery technology portfolio.”
“Acquisition of Elektrofi announced, expected to close in Q4 2025.”
“Announced new $1 billion share repurchase program with expectation to repurchase at least $400 million in 2026.”